Five an­a­lyt­ics firms launch RWE lob­by­ing group to press Con­gress, FDA on guid­ance, Cures 2.0

With around 75% of all new drug ap­provals in 2020 in­clud­ing re­al world ev­i­dence in their sub­mis­sions to FDA, da­ta and an­a­lyt­ics firms Ae­tion, Flat­iron Health (an in­de­pen­dent af­fil­i­ate of Roche), IQVIA, Syapse, and Tem­pus are gear­ing up to press Con­gress and the FDA even fur­ther on us­ing RWE to ac­cel­er­ate drug de­vel­op­ment.

The com­pa­nies all chipped in to hire the lob­by­ing firm Cov­ing­ton to run the new RWE Al­liance. Ken Tarkoff, CEO of Syapse, told End­points News in an in­ter­view that as the or­ga­ni­za­tion grows over time, the al­liance is hop­ing new com­pa­nies will pay to be mem­bers of the al­liance to fur­ther the cause.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER